- EssilorLuxottica enhances its med-tech portfolio with the strategic acquisition of Optegra.
- Wall Street analysts offer varied price targets for ESLOY, implying potential downside.
- Current brokerage recommendations suggest holding the stock.
EssilorLuxottica (ESLOY, Financial) has taken a significant step in its strategic growth by acquiring Optegra, a leading ophthalmology group in Europe. This acquisition substantially strengthens EssilorLuxottica's med-tech portfolio, allowing it to expand its reach in advanced eye care services and technologies. Through this move, EssilorLuxottica aims to deepen its capabilities in AI-assisted diagnostics and surgical solutions across several countries.
Wall Street Analysts Forecast
Wall Street analysts have provided one-year price targets for Essilorluxottica (ESLOY, Financial), averaging at $135.65. The high estimate reaches $150.00, while the low is set at $121.29. These figures suggest a potential downside of 2.00% from the current trading price of $138.41. For a more comprehensive analysis, investors can visit the Essilorluxottica (ESLOY) Forecast page.
In terms of brokerage recommendations, Essilorluxottica's (ESLOY, Financial) consensus rating is a 3.0, categorizing it as a "Hold." This rating derives from a scale where 1 indicates a "Strong Buy" and 5 suggests a "Sell," offering valuable insight into investor sentiment.
According to GuruFocus estimates, Essilorluxottica's (ESLOY, Financial) estimated GF Value for the upcoming year is predicted to be $122.17. This estimate reflects an implied downside of 11.73% from its current price of $138.41. The GF Value is an insightful metric that assesses the fair value of the stock, calculated considering historical trading multiples, past business growth, and future performance projections. More intricate details can be found on the Essilorluxottica (ESLOY) Summary page.
